ZK 304709Alternative Names: ZK-304709
Latest Information Update: 17 Mar 2010
At a glance
- Originator Bayer Schering Pharma
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 05 May 2005 Phase-I clinical trials in Cancer in Germany (PO)